Hong Kong – A crucial player in genomic integrity maintenance, DNA Polymerase Theta (Polθ) provides a potential synthetic lethal relationship in BRCA-deficient tumors, which are particularly prevalent in certain tumor types including triple-negative breast cancers (TNBC) and ovarian cancers. In fact, BRCA-deficient tumors account for 11-16% of TNBC cases, and...
Latest News
SAN ANTONIO, TX – A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to extend survival for patients with glioblastoma, the most common primary brain tumor in adults. Results of a trial led by the university revealed that...
SAN ANTONIO, TX – Research led by in part by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) finds that the most common cerebral small-vessel disease feature seen in brain magnetic resonance imaging is a primary vascular factor associated with dementia risk. Results of...
SAN ANTONIO, Texas – Researchers at the University of Texas Health Science Center at San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation, bringing new hope for survival. Ironically, the scientists found that the customary treatment for glioblastoma, ionizing radiation,...
Dallas, Texas – UT Southwestern Medical Center researchers have identified a genetic mutation that slows the growth of melanoma and potentially other cancers by harnessing the power of the immune system. Their findings, published in the Journal of Experimental Medicine, could lead to new treatments that improve outcomes from existing...
SALT LAKE CITY, Utah — While many babies are born without issues on a daily basis, there are quite a few who are born early and with some complications. Those babies end up in the Neonatal Intensive Care Unit (NICU), which is where Dr. Sabrina Malone Jenkins works. The Neonatologist...
EL PASO, Texas – Researchers at The University of Texas at El Paso have identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy. Renato Aguilera, Ph.D., a professor in the Department of Biological Sciences, is the principal...
EL PASO, Texas — Researchers at The University of Texas at El Paso are developing a new therapeutic approach that uses nanoparticles for the treatment of skin and pulmonary fibrosis, conditions that can result in severe damage to the body’s tissues. Md Nurunnabi, Ph.D., is an associate professor in UTEP’s...
Houston, TX – A medication that appeared to stabilize the function and shape of red blood cells in an earlier study for patients with sickle cell disease is now part of a Phase III clinical trial that is open for enrollment at UTHealth Houston. The trial, led locally by Modupe Idowu,...
Houston, Texas – A four-year, $3.4 million grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome (ARDS) has been awarded to UTHealth Houston researchers by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. The study led by principal investigators Holger Eltzschig,...